Comparative efficacy and cognitive function of magnetic seizure therapy and electroconvulsive therapy for major depressive disorder: a systematic review and meta-analysis of randomized controlled trials.
Magnetic seizure therapy (MST), as a novel physical therapy technique, has demonstrated significant efficacy in the treatment of depression. Previous systematic reviews and meta-analyses have preliminarily confirmed its clinical value. This study conducts a meta-analysis based on updated randomized controlled trials to evaluate the differences in efficacy between MST and electroconvulsive therapy (ECT) in patients with major depressive disorder (MDD), as well as their effects on cognitive function.
We conducted a systematic search of PubMed, Embase, the Cochrane Library, Web of Science, Ovid, ProQuest, and CNKI databases for randomized controlled trials published up to March 1, 2026. The selection of studies strictly followed the Cochrane Risk of Bias in Randomized Trials tool, and the meta-analysis was conducted in accordance with the Cochrane Systematic Reviewer's Manual. Data from 429 patients across 6 studies were included in the quantitative synthesis.
The results showed that post-treatment depression scale scores in the MST group were 0.329 higher than those in the ECT group (95% CI: 0.119-0.539, I² = 9.4%, P = 0.0021), suggesting that the antidepressant efficacy of MST was inferior to that of ECT. In the neurocognitive subgroup analysis, MST performed significantly better than ECT in verbal fluency (SMD = 0.75, 95% CI: 0.19-1.31, P = 0.0088), immediate memory (SMD = 0.68, 95% CI: 0.35-1.01, P < 0.0001), delayed memory (SMD = 0.61, 95% CI: 0.28-0.94, P = 0.0003), and verbal learning (SMD = 0.57, 95% CI: 0.18-0.95, P = 0.0037).
Our evidence-based study conducted a meta-analysis of the antidepressant efficacy of MST and its effects on cognitive function. The evidence from this study suggests that MST may be slightly less effective than ECT in treating depression but may offer advantages in terms of cognitive preservation; further research is needed to confirm these findings.
We conducted a systematic search of PubMed, Embase, the Cochrane Library, Web of Science, Ovid, ProQuest, and CNKI databases for randomized controlled trials published up to March 1, 2026. The selection of studies strictly followed the Cochrane Risk of Bias in Randomized Trials tool, and the meta-analysis was conducted in accordance with the Cochrane Systematic Reviewer's Manual. Data from 429 patients across 6 studies were included in the quantitative synthesis.
The results showed that post-treatment depression scale scores in the MST group were 0.329 higher than those in the ECT group (95% CI: 0.119-0.539, I² = 9.4%, P = 0.0021), suggesting that the antidepressant efficacy of MST was inferior to that of ECT. In the neurocognitive subgroup analysis, MST performed significantly better than ECT in verbal fluency (SMD = 0.75, 95% CI: 0.19-1.31, P = 0.0088), immediate memory (SMD = 0.68, 95% CI: 0.35-1.01, P < 0.0001), delayed memory (SMD = 0.61, 95% CI: 0.28-0.94, P = 0.0003), and verbal learning (SMD = 0.57, 95% CI: 0.18-0.95, P = 0.0037).
Our evidence-based study conducted a meta-analysis of the antidepressant efficacy of MST and its effects on cognitive function. The evidence from this study suggests that MST may be slightly less effective than ECT in treating depression but may offer advantages in terms of cognitive preservation; further research is needed to confirm these findings.